[1] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017,67:145-172.
[2] Chuang N,Gross RG,Odin JA.Update on the epidemiology of primary biliary cirrhosis.Expert Rev Gastroen terol Hepatol,2011,5:583-590.
[3] Gross RG, Odin JA. Recent advances in the epidemiology of primary biliary cirrhosis.Clin Liver Dis,2008,12:289-303.
[4] Ishibashi H,Shimoda SJ,Gershwin ME.The immune response to mitochondrial autoantigens.Semin Liver Dis,2005,25:337-346.
[5] 刘宁,谭立明,董叶,等.原发性胆汁性肝硬化患者自身抗体测定的意义.世界华人消化杂志,2007,15:2358-2361.
[6] 陈凤英,刘晓丽,蔡军.原发性胆汁性肝硬化患者外周血NKT细胞体外活化剂相关细胞因子表达分析.中华检验医学杂志,2010,33:735-739.
[7] Chang CH,Chen YH,Zhang WC,et al.Innate immunity drives the Initiation of a murine model of primary biliary cirrhosis.PLoS One,2015,10:1-13.
[8] Hareda K,Isse K,Nakanuma Y.Interferon gamma aceelerales NF-kappaB activation of biliary epithelial cells induced by Toll-like receptor and ligand interaction.J Clin Pathol,2006,59:184-190. |
